E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Chronic atrophic candidosis or denture stomatitis is the commonest form of oral candidosis. It is an opportunistic infection related to an inflammatory process in the mucosal surface beneath dentures and is a common finding among edentulous patients attending dental schools and those resident in homes for the elderly. The prevalence of this type of candidosis has been increasing with more than 50% of subjects in some studies of elderly denture wearers being reported to have candidosis. |
|
E.1.1.1 | Medical condition in easily understood language |
A Candida infection in the oral cavity is a common finding among elderly patients attending dental schools and those resident in homes for the elderly. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Mouth and tooth diseases [C07] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The applicants have been investigating several new methods for treating common conditions of the oral mucosa. One particular area of interest follows on from the demonstration that monocaprin, a derivative of capric acid, is active against oral yeasts and has, therefore, potential as an alternative treatment for oral yeast infections such as chronic atrophic candidosis or denture stomatitis. The aim of this study is to follow on from the previously-demonstrated in vitro anti-candidal activity into a clinical study by incorporating monocaprin into denture adhesives and mucoadhesive hydrogel. These products will then be tested in clinical trials. It is hoped that these denture products would be improved by imparting anti-candidal activity adjacent to the oral mucosa. |
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
The study will be carried out at the clinic of the Landakot geriatric hospital and the dental clinic of the Faculty of Odontology at the University of Iceland. Subjects will be selected from the group of patients attending the clinic. Patients will be edentulous in the upper jaw and use their dentures routinely. The study will be explained to each individual by the pharmacy students, with supervision and assistance where necessary. Patients must give their informed consent to the study. |
|
E.4 | Principal exclusion criteria |
Participants that are cognitively impared will be excluded from the trial. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
There will be 60 participants in the study and they will be divided into three groups with 20 participants in each. Group I will receive treatement with dental adhesive containing monocaprin, group II will receive treament with tissue liner containing monocaprin and Group III will be not receive treatment but will function as control. The study will last for four weeks. The participants will be taught how to use the dental adhesive and the mucoadhesive hydrogel and requested to use the monocaprin-containing preparations daily. Speciments will be taken at the beginning of the study, then in two weeks and in four weeks. Speciments will be taken at the beginning of the study, then in two weeks and in four weeks. Specimens will be collected using standard 1sq cm sponges that have been soaked in sterile saline and, using sterile tweezers, placed on i) the fitting surface of the denture; ii) the dorsum of the tongue and iii) the palatal mucosa for about 15 sec. Swabs are then removed and placed on the surface of agar culture plates. Plates will be transferred to the laboratory in the Faculty of Odontology and incubated at 37°C overnight. Following incubation the swabs will be removed and incubation continued for a further 24 h before the plates will be examined in a stereo-microscope. Colonies of yeasts will be counted.
Two weeks after the termination of treatment with a monocaprin containing preparation speciments will be taken to evaluated the extent of re-colonisation.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Speciments will be taken at the beginning of the study, then in two weeks and in four weeks. |
|
E.5.2 | Secondary end point(s) |
Speciments will be taken at the beginning of the study, then in two weeks and in four weeks. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Two weeks after the termination of treatment with monocaprin containing preparations speciments will be taken to evaluated the extent of re-colonisation. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | Yes |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
There 2 dosage forms containing monocaprin, a dental adhesive and a gel |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | 42 |